Genzada Pharmaceuticals Usa, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://genzada.com
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced CancerPancreatic CancerProstate Cancer MetastaticColo-rectal CancerSolid TumorSolid CarcinomaSolid Carcinoma of StomachHead and Neck Squamous Cell CarcinomaBasal Cell CarcinomaCutaneous T-cell Lymphoma
- Interventions
- Drug: GZ17-6.02Drug: Capecitabine
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Genzada Pharmaceuticals USA, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT03775525
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath